JILIN AODONG(SZ:000623) Zheng Quan Ri Bao·2025-04-23 16:37Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. reported a revenue of 2.611 billion yuan and a net profit of 1.551 billion yuan for 2024, with a debt-to-asset ratio of 11.27%, while actively adapting to changes in the pharmaceutical industry through a multi-driven development model of "pharmaceuticals + finance + health" [2][3] Group 1: Financial Performance - The company achieved a revenue of 2.611 billion yuan and a net profit attributable to shareholders of 1.551 billion yuan in 2024 [2] - The proposed cash dividend for 2024 is 3 yuan per 10 shares, totaling an estimated distribution of 352 million yuan, alongside a mid-year dividend of 239 million yuan, bringing the total cash dividends and share buybacks to 891 million yuan, which is 57.43% of the net profit [7] Group 2: Business Strategy - Jilin Aodong is focusing on building a competitive advantage across the entire pharmaceutical industry chain, including traditional Chinese medicine, chemical drugs, and health products, while enhancing its "pharmaceuticals + finance + health" multi-driven development model [3][4] - The company is implementing a marketing strategy centered on "big product groups + multiple product groups" to cultivate core products and strengthen channel management, aiming for a revenue of 2.274 billion yuan from its pharmaceutical segment [3][4] Group 3: Innovation and R&D - The company has established an innovative R&D system that integrates production, learning, and research, achieving significant results in the field of Chinese medicine formula granules [4][6] - Jilin Aodong is leveraging advanced research technologies and digital production to modernize and automate traditional Chinese medicine manufacturing, while also participating in the establishment of brand demonstration bases for Chinese medicinal materials [6][7]